Steven E Kahn

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1104610/publications.pdf

Version: 2024-02-01

298 papers 41,198 citations

91 h-index 197 g-index

302 all docs 302 docs citations

302 times ranked 39564 citing authors

#	Article	IF	CITATIONS
1	Association Between Change in Accelerometer-Measured and Self-Reported Physical Activity and Cardiovascular Disease in the Look AHEAD Trial. Diabetes Care, 2022, 45, 742-749.	4.3	10
2	Islet Autoimmunity Is Highly Prevalent and Associated With Diminished \hat{I}^2 -Cell Function in Patients With Type 2 Diabetes in the GRADE Study. Diabetes, 2022, 71, 1261-1271.	0.3	11
3	Effects of Intensive Lifestyle Intervention on All-Cause Mortality in Older Adults With Type 2 Diabetes and Overweight/Obesity: Results From the Look AHEAD Study. Diabetes Care, 2022, 45, 1252-1259.	4.3	23
4	Editorial Cycles and Continuity of <i>Diabetes Care</i> . Diabetes Care, 2022, 45, 1493-1494.	4.3	0
5	Leptin and Adiponectin Concentrations Independently Predict Future Accumulation of Visceral Fat in Nondiabetic Japanese Americans. Obesity, 2021, 29, 233-239.	1.5	4
6	Within-Trial Cost-Effectiveness of a Structured Lifestyle Intervention in Adults With Overweight/Obesity and Type 2 Diabetes: Results From the Action for Health in Diabetes (Look AHEAD) Study. Diabetes Care, 2021, 44, 67-74.	4.3	10
7	Association of Baseline Characteristics With Insulin Sensitivity and \hat{I}^2 -Cell Function in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness (GRADE) Study Cohort. Diabetes Care, 2021, 44, 340-349.	4.3	16
8	OGTT Glucose Response Curves, Insulin Sensitivity, and \hat{I}^2 -Cell Function in RISE: Comparison Between Youth and Adults at Randomization and in Response to Interventions to Preserve \hat{I}^2 -Cell Function. Diabetes Care, 2021, 44, 817-825.	4.3	20
9	Sexâ€related differences in cognitive trajectories in older individuals with type 2 diabetes and overweight or obesity. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2021, 7, e12160.	1.8	7
10	Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes: the CARMELINA randomized controlled trial. CKJ: Clinical Kidney Journal, 2021, 14, 226-236.	1.4	6
11	Obstructive Sleep Apnea, Glucose Tolerance, and \hat{i}^2 -Cell Function in Adults With Prediabetes or Untreated Type 2 Diabetes in the Restoring Insulin Secretion (RISE) Study. Diabetes Care, 2021, 44, 993-1001.	4.3	16
12	Type 2 Diabetes Subgroups, Risk for Complications, and Differential Effects Due to an Intensive Lifestyle Intervention. Diabetes Care, 2021, 44, 1203-1210.	4.3	22
13	Precision and accuracy of hyperglycemic clamps in a multicenter study. American Journal of Physiology - Endocrinology and Metabolism, 2021, 320, E797-E807.	1.8	4
14	Association of glycemia with insulin sensitivity and \hat{l}^2 -cell function in adults with early type 2 diabetes on metformin alone. Journal of Diabetes and Its Complications, 2021, 35, 107912.	1,2	5
15	\hat{l}^2 -cell function in black South African women: exploratory associations with insulin clearance, visceral and ectopic fat. Endocrine Connections, 2021, 10, 550-560.	0.8	3
16	Hyperglucagonemia Does Not Explain the \hat{I}^2 -Cell Hyperresponsiveness and Insulin Resistance in Dysglycemic Youth Compared With Adults: Lessons From the RISE Study. Diabetes Care, 2021, 44, 1961-1969.	4.3	9
17	The \hat{I}^2 Cell in Diabetes: Integrating Biomarkers With Functional Measures. Endocrine Reviews, 2021, 42, 528-583.	8.9	21
18	Baseline Predictors of Glycemic Worsening in Youth and Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes in the Restoring Insulin Secretion (RISE) Study. Diabetes Care, 2021, 44, 1938-1947.	4.3	16

#	Article	IF	Citations
19	Effect of Medical and Surgical Interventions on α-Cell Function in Dysglycemic Youth and Adults in the RISE Study. Diabetes Care, 2021, 44, 1948-1960.	4.3	2
20	On the causal relationships between hyperinsulinaemia, insulin resistance, obesity and dysglycaemia in type 2 diabetes: Reply to Johnson JD [letter]. Diabetologia, 2021, 64, 2345-2347.	2.9	6
21	Changes in mood and healthâ€related quality of life in Look AHEAD 6 years after termination of the lifestyle intervention. Obesity, 2021, 29, 1294-1308.	1.5	5
22	Legacy of a 10-Year Multidomain Lifestyle Intervention on the Cognitive Trajectories of Individuals with Overweight/Obesity and Type 2 Diabetes Mellitus. Dementia and Geriatric Cognitive Disorders, 2021, 50, 237-249.	0.7	5
23	Lower High-Density Lipoprotein Cholesterol Concentration Is Independently Associated with Greater Future Accumulation of Intra-Abdominal Fat. Endocrinology and Metabolism, 2021, 36, 835-844.	1.3	2
24	Shape of the OGTT glucose response curve: relationship with \hat{l}^2 -cell function and differences by sex, race, and BMI in adults with early type 2 diabetes treated with metformin. BMJ Open Diabetes Research and Care, 2021, 9, e002264.	1.2	12
25	Loss of apoptosis repressor with caspase recruitment domain (ARC) worsens high fat diet-induced hyperglycemia in mice. Journal of Endocrinology, 2021, 251, 125-135.	1.2	0
26	A Lesson From 2020: Public Health Matters for Both COVID-19 and Diabetes. Diabetes Care, 2021, 44, 8-10.	4.3	8
27	Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet, The, 2021, 398, 1811-1824.	6.3	257
28	Islet Autoimmunity in Adults With Impaired Glucose Tolerance and Recently Diagnosed, Treatment Na \tilde{A} -ve Type 2 Diabetes in the Restoring Insulin SEcretion (RISE) Study. Frontiers in Immunology, 2021, 12, 640251.	2.2	2
29	Adiposity, related biomarkers, and type 2 diabetes after gestational diabetes: The Diabetes Prevention Program. Obesity, 2021, , .	1.5	2
30	Plasma amino acid profile, a biomarker for visceral adipose tissue that can substitute for waist circumference in Japanese Americans. Obesity Research and Clinical Practice, 2021, 15, 557-563.	0.8	2
31	Islet Autoimmunity in Adults With Impaired Glucose Tolerance and Recently Diagnosed, Treatment NaÃ-ve Type 2 Diabetes in the Restoring Insulin SEcretion (RISE) Study. Frontiers in Immunology, 2021, 12, 640251.	2.2	6
32	Interaction Between Type 2 Diabetes Prevention Strategies and Genetic Determinants of Coronary Artery Disease on Cardiometabolic Risk Factors. Diabetes, 2020, 69, 112-120.	0.3	13
33	History of Cardiovascular Disease, Intensive Lifestyle Intervention, and Cardiovascular Outcomes in the Look AHEAD Trial. Obesity, 2020, 28, 247-258.	1.5	8
34	Withdrawal of medications leads to worsening of <scp>OGTT</scp> parameters in youth with impaired glucose tolerance or <scp>recentlyâ€diagnosed</scp> type 2 diabetes. Pediatric Diabetes, 2020, 21, 1437-1446.	1.2	7
35	Comparison of twenty indices of insulin sensitivity in predicting type 2 diabetes in Japanese Americans: The Japanese American Community Diabetes Study. Journal of Diabetes and Its Complications, 2020, 34, 107731.	1.2	5
36	Low concentration IL- $1\hat{l}^2$ promotes islet amyloid formation by increasing hIAPP release from humanised mouse islets in vitro. Diabetologia, 2020, 63, 2385-2395.	2.9	10

#	Article	IF	CITATIONS
37	Tubular Secretory Clearance Is Associated With Whole-Body Insulin Clearance. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e3882-e3891.	1.8	3
38	Intensive Weight Loss Intervention and Cancer Risk in Adults with Type 2 Diabetes: Analysis of the Look AHEAD Randomized Clinical Trial. Obesity, 2020, 28, 1678-1686.	1.5	47
39	Early beta cell dysfunction vs insulin hypersecretion as the primary event in the pathogenesis of dysglycaemia. Diabetologia, 2020, 63, 2007-2021.	2.9	94
40	COVID-19 in People With Diabetes: Urgently Needed Lessons From Early Reports. Diabetes Care, 2020, 43, 1378-1381.	4.3	71
41	Daniel Porte Jr.: A Leader in Our Understanding of the Role of Defective Insulin Secretion and Action in Obesity and Type 2 Diabetes. Diabetes Care, 2020, 43, 704-709.	4.3	3
42	Weight Change 2 Years After Termination of the Intensive Lifestyle Intervention in the Look AHEAD Study. Obesity, 2020, 28, 893-901.	1.5	24
43	Short Report: Circulating microRNAs are associated with incident diabetes over 10 years in Japanese Americans. Scientific Reports, 2020, 10, 6509.	1.6	12
44	Impaired counterregulatory responses to hypoglycaemia following oral glucose in adults with cystic fibrosis. Diabetologia, 2020, 63, 1055-1065.	2.9	13
45	Effect of exercise training on insulin sensitivity, hyperinsulinemia and ectopic fat in black South African women: a randomized controlled trial. European Journal of Endocrinology, 2020, 183, 51-61.	1.9	14
46	Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial. Diabetes Care, 2020, 43, 1803-1812.	4.3	44
47	Intra-Abdominal Fat and High Density Lipoprotein Cholesterol Are Associated in a Non-Linear Pattern in Japanese-Americans. Diabetes and Metabolism Journal, 2020, 44, 277.	1.8	4
48	Apolipoprotein B Levels Predict Future Development of Hypertension Independent of Visceral Adiposity and Insulin Sensitivity. Endocrinology and Metabolism, 2020, 35, 351-358.	1.3	8
49	Genetic ancestry markers and difference in A1c between African-American and White in the Diabetes Prevention Program. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 328-336.	1.8	12
50	Regression From Prediabetes to Normal Glucose Regulation and Prevalence of Microvascular Disease in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes Care, 2019, 42, 1809-1815.	4.3	61
51	Does diabetes prevention translate into reduced long-term vascular complications of diabetes?. Diabetologia, 2019, 62, 1319-1328.	2.9	48
52	A Polygenic Lipodystrophy Genetic Risk Score Characterizes Risk Independent of BMI in the Diabetes Prevention Program. Journal of the Endocrine Society, 2019, 3, 1663-1677.	0.1	13
53	Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes. JAMA - Journal of the American Medical Association, 2019, 322, 1155.	3.8	423
54	RNA-seq-based identification of Star upregulation by islet amyloid formation. Protein Engineering, Design and Selection, 2019, 32, 67-76.	1.0	5

#	Article	lF	CITATIONS
55	A Call for Improved Reporting of Human Islet Characteristics in Research Articles. Diabetes, 2019, 68, 239-240.	0.3	21
56	Probing the Meaning of Persistent Propeptide Release in Type 1 Diabetes. Diabetes Care, 2019, 42, 183-185.	4.3	5
57	Change in CT-measured abdominal subcutaneous and visceral but not thigh fat areas predict future insulin sensitivity. Diabetes Research and Clinical Practice, 2019, 154, 17-26.	1.1	5
58	Association of Habitual Daily Physical Activity With Glucose Tolerance and Î ² -Cell Function in Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes From the Restoring Insulin Secretion (RISE) Study. Diabetes Care, 2019, 42, 1521-1529.	4.3	9
59	Lack of Durable Improvements in \hat{l}^2 -Cell Function Following Withdrawal of Pharmacological Interventions in Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes. Diabetes Care, 2019, 42, 1742-1751.	4.3	56
60	Long-term Effects of Metformin on Diabetes Prevention: Identification of Subgroups That Benefited Most in the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study. Diabetes Care, 2019, 42, 601-608.	4.3	82
61	Hepatic Insulin Extraction in NAFLD Is Related to Insulin Resistance Rather Than Liver Fat Content. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 1855-1865.	1.8	45
62	Higher High Density Lipoprotein 2 (HDL2) to Total HDL Cholesterol Ratio Is Associated with a Lower Risk for Incident Hypertension. Diabetes and Metabolism Journal, 2019, 43, 114.	1.8	9
63	Loss of perlecan heparan sulfate glycosaminoglycans lowers body weight and decreases islet amyloid deposition in human islet amyloid polypeptide transgenic mice. Protein Engineering, Design and Selection, 2019, 32, 95-102.	1.0	8
64	Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA. Circulation, 2019, 139, 351-361.	1.6	126
65	A call for improved reporting of human islet characteristics in research articles. Diabetologia, 2019, 62, 209-211.	2.9	19
66	Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk. JAMA - Journal of the American Medical Association, 2019, 321, 69.	3.8	830
67	Metabolic Clusters and Outcomes in Older Adults: The Cardiovascular Health Study. Journal of the American Geriatrics Society, 2018, 66, 289-296.	1.3	19
68	Review of methods for measuring βâ€cell function: <scp>D</scp> esign considerations from the <scp>R</scp> estoring <scp>I</scp> nsulin <scp>S</scp> ecretion (<scp>RISE</scp>) <scp>C</scp> onsortium. Diabetes, Obesity and Metabolism, 2018, 20, 14-24.	2,2	71
69	Physical Function Following a Long-Term Lifestyle Intervention Among Middle Aged and Older Adults With Type 2 Diabetes: The Look AHEAD Study. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2018, 73, 1552-1559.	1.7	39
70	Change in visceral adiposity is an independent predictor of future arterial pulse pressure. Journal of Hypertension, 2018, 36, 299-305.	0.3	8
71	Association of Thigh Muscle Mass with Insulin Resistance and Incident Type 2 Diabetes Mellitus in Japanese Americans. Diabetes and Metabolism Journal, 2018, 42, 488.	1.8	35
72	Design and validation of a novel estimator of visceral adipose tissue area and comparison to existing adiposity surrogates. Journal of Diabetes and Its Complications, 2018, 32, 1062-1067.	1.2	7

#	Article	IF	CITATIONS
73	Impact of Gastric Banding Versus Metformin on \hat{I}^2 -Cell Function in Adults With Impaired Glucose Tolerance or Mild Type 2 Diabetes. Diabetes Care, 2018, 41, 2544-2551.	4.3	27
74	Predictors of Incident Type 2 Diabetes Mellitus in Japanese Americans with Normal Fasting Glucose Level. Diabetes and Metabolism Journal, 2018, 42, 198.	1.8	3
75	Natural history of impaired glucose tolerance in Japanese Americans: Change in visceral adiposity is associated with remission from impaired glucose tolerance to normal glucose tolerance. Diabetes Research and Clinical Practice, 2018, 142, 303-311.	1.1	1
76	Impact of Insulin and Metformin Versus Metformin Alone on \hat{l}^2 -Cell Function in Youth With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes. Diabetes Care, 2018, 41, 1717-1725.	4.3	112
77	Metabolic Contrasts Between Youth and Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes: I. Observations Using the Hyperglycemic Clamp. Diabetes Care, 2018, 41, 1696-1706.	4.3	127
78	Use of the PET ligand florbetapir for in vivo imaging of pancreatic islet amyloid deposits in hIAPP transgenic mice. Diabetologia, 2018, 61, 2215-2224.	2.9	8
79	Novel approaches to restore beta cell function in prediabetes and type 2 diabetes. Diabetologia, 2018, 61, 1895-1901.	2.9	35
80	An Exercise Intervention to Unravel the Mechanisms Underlying Insulin Resistance in a Cohort of Black South African Women: Protocol for a Randomized Controlled Trial and Baseline Characteristics of Participants. JMIR Research Protocols, 2018, 7, e75.	0.5	19
81	Predictors of Incident Type 2 Diabetes Mellitus in Japanese Americans with Normal Fasting Glucose Level. Diabetes and Metabolism Journal, 2018, , .	1.8	0
82	<i>Diabetes Care</i> : "Taking It to the Limit One More Time― Diabetes Care, 2017, 40, 3-6.	4.3	7
83	Evidence That the Sympathetic Nervous System Elicits Rapid, Coordinated, and Reciprocal Adjustments of Insulin Secretion and Insulin Sensitivity During Cold Exposure. Diabetes, 2017, 66, 823-834.	0.3	34
84	Response to Comment on Cefalu et al. Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a <i>Diabetes Care</i> Editors' Expert Forum. Diabetes Care 2016;39:1186–1201. Diabetes Care, 2017, 40, e23-e24.	4.3	1
85	Greater visceral abdominal fat is associated with a lower probability of conversion of prehypertension to normotension. Journal of Hypertension, 2017, 35, 1213-1218.	0.3	10
86	Chronic kidney disease and obesity bias surrogate estimates of insulin sensitivity compared with the hyperinsulinemic euglycemic clamp. American Journal of Physiology - Endocrinology and Metabolism, 2017, 312, E175-E182.	1.8	5
87	Variation in Maturity-Onset Diabetes of the Young Genes Influence Response to Interventions for Diabetes Prevention. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 2678-2689.	1.8	16
88	Effect of a long-term intensive lifestyle intervention on prevalence of cognitive impairment. Neurology, 2017, 88, 2026-2035.	1.5	59
89	Low Plasma Adiponectin Concentrations Predict Increases in Visceral Adiposity and Insulin Resistance. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 4626-4633.	1.8	36
90	Effects of combination of change in visceral fat and thigh muscle mass on the development of type 2 diabetes. Diabetes Research and Clinical Practice, 2017, 134, 131-138.	1.1	11

#	Article	IF	Citations
91	Apoptosis Repressor With Caspase Recruitment Domain Ameliorates Amyloid-Induced \hat{I}^2 -Cell Apoptosis and JNK Pathway Activation. Diabetes, 2017, 66, 2636-2645.	0.3	17
92	The Effect of Intentional Weight Loss on Fracture Risk in Persons With Diabetes: Results From the Look AHEAD Randomized Clinical Trial. Journal of Bone and Mineral Research, 2017, 32, 2278-2287.	3.1	57
93	Metformin for diabetes prevention: insights gained from the Diabetes Prevention Program/Diabetes Prevention Program Outcomes Study. Diabetologia, 2017, 60, 1601-1611.	2.9	129
94	SGLT2 Inhibitorsâ€"Sweet Success for Diabetic Kidney Disease?. Journal of the American Society of Nephrology: JASN, 2017, 28, 7-10.	3.0	19
95	Relationships of the early insulin secretory response and oral disposition index with gastric emptying in subjects with normal glucose tolerance. Physiological Reports, 2017, 5, e13122.	0.7	11
96	Physical activity and metabolic health in chronic kidney disease: a cross-sectional study. BMC Nephrology, 2016, 17, 187.	0.8	20
97	Inhibition of Insulin-Degrading Enzyme Does Not Increase Islet Amyloid Deposition in Vitro. Endocrinology, 2016, 157, 3462-3468.	1.4	5
98	Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a Diabetes Care Editors' Expert Forum. Diabetes Care, 2016, 39, 1186-1201.	4.3	113
99	The S20G substitution in hIAPP is more amyloidogenic and cytotoxic than wild-type hIAPP in mouse islets. Diabetologia, 2016, 59, 2166-2171.	2.9	37
100	Lifestyle Intervention for Weight Loss and Cardiometabolic Changes in the Setting of Glucokinase Regulatory Protein Inhibition. Circulation: Cardiovascular Genetics, 2016, 9, 71-78.	5.1	6
101	Lifestyle and Metformin Ameliorate Insulin Sensitivity Independently of the Genetic Burden of Established Insulin Resistance Variants in Diabetes Prevention Program Participants. Diabetes, 2016, 65, 520-526.	0.3	34
102	Increased Visceral Adipose Tissue Is an Independent Predictor for Future Development of Atherogenic Dyslipidemia. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 678-685.	1.8	54
103	Impaired Glucose and Insulin Homeostasis in Moderate-Severe CKD. Journal of the American Society of Nephrology: JASN, 2016, 27, 2861-2871.	3.0	83
104	Response to Comments on Nolan et al. Insulin Resistance as a Physiological Defense Against Metabolic Stress: Implications for the Management of Subsets of Type 2 Diabetes. Diabetes 2015;64:673–686. Diabetes, 2015, 64, e38-e39.	0.3	4
105	Matrix Metalloproteinase-9 Protects Islets from Amyloid-induced Toxicity. Journal of Biological Chemistry, 2015, 290, 30475-30485.	1.6	12
106	Optimum BMI Cut Points to Screen Asian Americans for Type 2 Diabetes. Diabetes Care, 2015, 38, 814-820.	4.3	108
107	Insulin Resistance as a Physiological Defense Against Metabolic Stress: Implications for the Management of Subsets of Type 2 Diabetes. Diabetes, 2015, 64, 673-686.	0.3	165
108	Changes in body composition over 8 years in a randomized trial of a lifestyle intervention: The look AHEAD study. Obesity, 2015, 23, 565-572.	1.5	55

#	Article	IF	CITATIONS
109	Change in Intra-Abdominal Fat Predicts the Risk of Hypertension in Japanese Americans. Hypertension, 2015, 66, 134-140.	1.3	36
110	Determination of Optimal Sample Size for Quantification of \hat{l}^2 -Cell Area, Amyloid Area and \hat{l}^2 -Cell Apoptosis in Isolated Islets. Journal of Histochemistry and Cytochemistry, 2015, 63, 663-673.	1.3	18
111	Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA $<$ sup $>$ Â $^{\odot}<$ /sup $>$). Diabetes and Vascular Disease Research, 2015, 12, 164-174.	0.9	197
112	Medications for type 2 diabetes: how will we be treating patients in 50Âyears?. Diabetologia, 2015, 58, 1735-1739.	2.9	12
113	Differential Association Between HDL Subclasses and the Development of Type 2 Diabetes in a Prospective Study of Japanese Americans. Diabetes Care, 2015, 38, 2100-2105.	4.3	21
114	Hepatic Insulin Resistance Following Chronic Activation of the CREB Coactivator CRTC2. Journal of Biological Chemistry, 2015, 290, 25997-26006.	1.6	26
115	Ethnic differences in hepatic and systemic insulin sensitivity and their associated determinants in obese black and white South African women. Diabetologia, 2015, 58, 2647-2652.	2.9	39
116	Genetic Predisposition to Weight Loss and Regain With Lifestyle Intervention: Analyses From the Diabetes Prevention Program and the Look AHEAD Randomized Controlled Trials. Diabetes, 2015, 64, 4312-4321.	0.3	72
117	Factors Affecting the Decline in Incidence of Diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes, 2015, 64, 989-998.	0.3	43
118	The Look AHEAD Trial: Bone Loss at 4-Year Follow-up in Type 2 Diabetes. Diabetes Care, 2014, 37, 2822-2829.	4.3	33
119	Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet, The, 2014, 383, 1068-1083.	6.3	1,230
120	Impact of Intensive Lifestyle Intervention on Depression and Health-Related Quality of Life in Type 2 Diabetes: The Look AHEAD Trial. Diabetes Care, 2014, 37, 1544-1553.	4.3	178
121	Effects of Weight Loss, Weight Cycling, and Weight Loss Maintenance on Diabetes Incidence and Change in Cardiometabolic Traits in the Diabetes Prevention Program. Diabetes Care, 2014, 37, 2738-2745.	4.3	97
122	Impact of an Intensive Lifestyle Intervention on Use and Cost of Medical Services Among Overweight and Obese Adults With Type 2 Diabetes: The Action for Health in Diabetes. Diabetes Care, 2014, 37, 2548-2556.	4.3	144
123	The Influence of Rare Genetic Variation in <i>SLC30A8</i> on Diabetes Incidence and \hat{I}^2 -Cell Function. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E926-E930.	1.8	20
124	We Can Change the Natural History of Type 2 Diabetes. Diabetes Care, 2014, 37, 2668-2676.	4.3	75
125	Islet amyloid formation is an important determinant for inducing islet inflammation in high-fat-fed human IAPP transgenic mice. Diabetologia, 2014, 57, 1884-1888.	2.9	68
126	Michaela Diamant, 11 April 1962–9 April 2014. Diabetologia, 2014, 57, 1271-1272.	2.9	1

#	Article	IF	Citations
127	The relative associations of \hat{l}^2 -cell function and insulin sensitivity with glycemic status and incident glycemic progression in migrant Asian Indians in the United States: The MASALA study. Journal of Diabetes and Its Complications, 2014, 28, 45-50.	1.2	46
128	Serum ferritin is associated with non-alcoholic fatty liver disease and decreased \hat{l} -cell function in non-diabetic men and women. Journal of Diabetes and Its Complications, 2014, 28, 177-184.	1.2	26
129	Adipocytokines as features of the metabolic syndrome determined using confirmatory factor analysis. Annals of Epidemiology, 2013, 23, 415-421.	0.9	16
130	Glucose Levels and Risk of Dementia. New England Journal of Medicine, 2013, 369, 540-548.	13.9	696
131	Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: Rationale for the active-comparator CAROLINA trial. Diabetes and Vascular Disease Research, 2013, 10, 289-301.	0.9	132
132	A Novel Risk Classification Paradigm for Patients With Impaired Glucose Tolerance and High Cardiovascular Risk. American Journal of Cardiology, 2013, 112, 231-237.	0.7	5
133	Impact of differences in glucose tolerance on the prevalence of a negative insulinogenic index. Journal of Diabetes and Its Complications, 2013, 27, 158-161.	1.2	16
134	Treatment with Thiazolidinediones., 2013,, 117-146.		0
135	Cardiovascular Effects of Intensive Lifestyle Intervention in Type 2 Diabetes. New England Journal of Medicine, 2013, 369, 145-154.	13.9	2,294
136	Direct Autocrine Action of Insulin on \hat{l}^2 -Cells: Does It Make Physiological Sense?. Diabetes, 2013, 62, 2157-2163.	0.3	85
137	Incretin Therapy and Islet Pathology: A Time for Caution. Diabetes, 2013, 62, 2178-2180.	0.3	57
138	Paricalcitol does not improve glucose metabolism in patients with stage 3–4 chronic kidney disease. Kidney International, 2013, 83, 323-330.	2.6	44
139	Change in Visceral Adiposity Independently Predicts a Greater Risk of Developing Type 2 Diabetes Over 10 Years in Japanese Americans. Diabetes Care, 2013, 36, 289-293.	4.3	89
140	Patterns of Insulin Concentration During the OGTT Predict the Risk of Type 2 Diabetes in Japanese Americans. Diabetes Care, 2013, 36, 1229-1235.	4.3	84
141	Neprilysin Deficiency Protects Against Fat-Induced Insulin Secretory Dysfunction by Maintaining Calcium Influx. Diabetes, 2013, 62, 1593-1601.	0.3	19
142	Quantifying Â-Cells in Health and Disease: The Past, the Present, and the Need. Diabetes Care, 2013, 36, 4-5.	4.3	101
143	Rationale and Design of the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). Diabetes Care, 2013, 36, 2254-2261.	4.3	217
144	Variation at the melanocortin 4 receptor gene and response to weightâ€loss interventions in the diabetes prevention program. Obesity, 2013, 21, E520-6.	1.5	36

#	Article	IF	CITATIONS
145	Human Cardiovascular Disease IBC Chip-Wide Association with Weight Loss and Weight Regain in the Look AHEAD Trial. Human Heredity, 2013, 75, 160-174.	0.4	22
146	Visceral fat resection in humans: Effect on insulin sensitivity, betaâ€cell function, adipokines, and inflammatory markers. Obesity, 2013, 21, E182-9.	1.5	59
147	Matrix Metalloproteinase-9 Reduces Islet Amyloid Formation by Degrading Islet Amyloid Polypeptide. Journal of Biological Chemistry, 2013, 288, 3553-3559.	1.6	32
148	Maternal Physical Activity and Insulin Action in Pregnancy and Their Relationships With Infant Body Composition. Diabetes Care, 2013, 36, 267-269.	4.3	16
149	Genetic Predictors of Weight Loss and Weight Regain After Intensive Lifestyle Modification, Metformin Treatment, or Standard Care in the Diabetes Prevention Program. Diabetes Care, 2012, 35, 363-366.	4.3	101
150	Risk factors for type 2 diabetes: Lessons learned from Japanese Americans in Seattle. Journal of Diabetes Investigation, 2012, 3, 212-224.	1.1	37
151	Colesevelam Improves Oral but Not Intravenous Glucose Tolerance by a Mechanism Independent of Insulin Sensitivity and \hat{l}^2 -Cell Function. Diabetes Care, 2012, 35, 1119-1125.	4.3	51
152	Midcourse correction to a clinical trial when the event rate is underestimated: the Look AHEAD (Action for Health in Diabetes) Study. Clinical Trials, 2012, 9, 113-124.	0.7	34
153	Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study. Lancet, The, 2012, 379, 2243-2251.	6. 3	384
154	Effects of Genetic Variants Previously Associated with Fasting Glucose and Insulin in the Diabetes Prevention Program. PLoS ONE, 2012, 7, e44424.	1.1	39
155	Effect of 1 year of an intentional weight loss intervention on bone mineral density in type 2 diabetes: Results from the look AHEAD randomized trial. Journal of Bone and Mineral Research, 2012, 27, 619-627.	3.1	68
156	Obesity and Type 2 Diabetes: What Can Be Unified and What Needs to Be Individualized?. Diabetes Care, 2011, 34, 1424-1430.	4.3	214
157	Gestational Diabetes or Lesser Degrees of Glucose Intolerance and Risk of Preeclampsia. Hypertension in Pregnancy, 2011, 30, 153-163.	0.5	39
158	\hat{l}^2 -Cell Loss and \hat{l}^2 -Cell Apoptosis in Human Type 2 Diabetes Are Related to Islet Amyloid Deposition. American Journal of Pathology, 2011, 178, 2632-2640.	1.9	271
159	Physical activity, sedentary behaviors, and estimated insulin sensitivity and secretion in pregnant and non-pregnant women. BMC Pregnancy and Childbirth, $2011,11,44.$	0.9	58
160	Diet Intervention and Cerebrospinal Fluid Biomarkers in Amnestic Mild Cognitive Impairment. Archives of Neurology, 2011, 68, 743-52.	4.9	122
161	Triglyceride Response to an Intensive Lifestyle Intervention Is Enhanced in Carriers of the <i> GCKR </i> Pro446Leu Polymorphism. Journal of Clinical Endocrinology and Metabolism, 2011, 96, E1142-E1147.	1.8	37
162	Reduced Gluteal Expression of Adipogenic and Lipogenic Genes in Black South African Women Is Associated with Obesity-Related Insulin Resistance. Journal of Clinical Endocrinology and Metabolism, 2011, 96, E2029-E2033.	1.8	36

#	Article	IF	CITATIONS
163	Effects of Rosiglitazone, Glyburide, and Metformin on Î ² -Cell Function and Insulin Sensitivity in ADOPT. Diabetes, 2011, 60, 1552-1560.	0.3	208
164	Obesity and Type 2 Diabetes: What Can Be Unified and What Needs to Be Individualized?. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 1654-1663.	1.8	384
165	Updated Genetic Score Based on 34 Confirmed Type 2 Diabetes Loci Is Associated With Diabetes Incidence and Regression to Normoglycemia in the Diabetes Prevention Program. Diabetes, 2011, 60, 1340-1348.	0.3	172
166	Renal Function in Type 2 Diabetes with Rosiglitazone, Metformin, and Glyburide Monotherapy. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 1032-1040.	2.2	64
167	Plasma sterol evidence for decreased absorption and increased synthesis of cholesterol in insulin resistance and obesity. American Journal of Clinical Nutrition, 2011, 94, 1182-1188.	2.2	40
168	What's Next for Diabetes Prevention?. Diabetes Care, 2011, 34, 1678-1680.	4.3	2
169	Ethnic differences in serum lipoproteins and their determinants in South African women. Metabolism: Clinical and Experimental, 2010, 59, 1341-1350.	1.5	69
170	Insulin Resistance is the Best Predictor of the Metabolic Syndrome in Subjects With a Firstâ€Degree Relative With Type 2 Diabetes. Obesity, 2010, 18, 1781-1787.	1.5	37
171	Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL- $\hat{\Pi}^2$ in type 2 diabetes. Nature Immunology, 2010, 11, 897-904.	7.0	1,149
172	Neprilysin Impedes Islet Amyloid Formation by Inhibition of Fibril Formation Rather Than Peptide Degradation. Journal of Biological Chemistry, 2010, 285, 18177-18183.	1.6	35
173	Rosiglitazone Decreases C-Reactive Protein to a Greater Extent Relative to Glyburide and Metformin Over 4 Years Despite Greater Weight Gain: Observations from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care, 2010, 33, 177-183.	4.3	40
174	Low Clusterin Levels in High-Density Lipoprotein Associate With Insulin Resistance, Obesity, and Dyslipoproteinemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 2528-2534.	1.1	72
175	Effect of Valsartan on the Incidence of Diabetes and Cardiovascular Events. New England Journal of Medicine, 2010, 362, 1477-1490.	13.9	588
176	Ghrelin Suppresses Glucose-Stimulated Insulin Secretion and Deteriorates Glucose Tolerance in Healthy Humans. Diabetes, 2010, 59, 2145-2151.	0.3	281
177	Effect of Nateglinide on the Incidence of Diabetes and Cardiovascular Events. New England Journal of Medicine, 2010, 362, 1463-1476.	13.9	430
178	Acute Effect of Roux-En-Y Gastric Bypass on Whole-Body Insulin Sensitivity: A Study with the Euglycemic-Hyperinsulinemic Clamp. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 3871-3875.	1.8	90
179	Current Status of Islet Cell Replacement and Regeneration Therapy. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 1034-1043.	1.8	84
180	Effect of Rosiglitazone, Metformin, and Glyburide on Bone Biomarkers in Patients with Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 134-142.	1.8	164

#	Article	IF	CITATIONS
181	Latent class analysis of the metabolic syndrome. Diabetes Research and Clinical Practice, 2010, 89, 88-93.	1.1	23
182	Intra-abdominal fat accumulation is greatest at younger ages in Japanese-American adults. Diabetes Research and Clinical Practice, 2010, 89, 58-64.	1.1	23
183	Effect of a 12-Month Intensive Lifestyle Intervention on Hepatic Steatosis in Adults With Type 2 Diabetes. Diabetes Care, 2010, 33, 2156-2163.	4.3	313
184	Regression From Pre-Diabetes to Normal Glucose Regulation in the Diabetes Prevention Program. Diabetes Care, 2009, 32, 1583-1588.	4.3	155
185	Oral Disposition Index Predicts the Development of Future Diabetes Above and Beyond Fasting and 2-h Glucose Levels. Diabetes Care, 2009, 32, 335-341.	4.3	457
186	Body Mass Index Is Associated with Increased Creatinine Clearance by a Mechanism Independent of Body Fat Distribution. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 3781-3788.	1.8	68
187	Enhanced cortisol production rates, free cortisol, and $11\hat{l}^2$ -HSD-1 expression correlate with visceral fat and insulin resistance in men: effect of weight loss. American Journal of Physiology - Endocrinology and Metabolism, 2009, 296, E351-E357.	1.8	94
188	The Association of ENPP1K121Q with Diabetes Incidence Is Abolished by Lifestyle Modification in the Diabetes Prevention Program. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 449-455.	1.8	48
189	Insulin Response in Relation to Insulin Sensitivity. Diabetes Care, 2009, 32, 860-865.	4.3	92
190	Glucose Control in Type 2 Diabetes. JAMA - Journal of the American Medical Association, 2009, 301, 1590.	3.8	14
191	Differential Effects of Abdominal Adipose Tissue Distribution on Insulin Sensitivity in Black and White South African Women. Obesity, 2009, 17, 1506-1512.	1.5	100
192	Association Between the 4 bp Proinsulin Gene Insertion Polymorphism (IVSâ€69) and Body Composition in Black South African Women. Obesity, 2009, 17, 1298-1300.	1.5	3
193	The prevention of type 2 diabetes. Nature Clinical Practice Endocrinology and Metabolism, 2008, 4, 382-393.	2.9	216
194	Adiponectin, Change in Adiponectin, and Progression to Diabetes in the Diabetes Prevention Program. Diabetes, 2008, 57, 980-986.	0.3	151
195	Reduced Adipogenic Gene Expression in Thigh Adipose Tissue Precedes Human Immunodeficiency Virus-Associated Lipoatrophy. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 959-966.	1.8	17
196	Rosiglitazone-Associated Fractures in Type 2 Diabetes. Diabetes Care, 2008, 31, 845-851.	4.3	498
197	Modestly Elevated Glucose Levels During Pregnancy Are Associated With a Higher Risk of Future Diabetes Among Women Without Gestational Diabetes Mellitus. Diabetes Care, 2008, 31, 1037-1039.	4.3	49
198	Visceral Adiposity, Not Abdominal Subcutaneous Fat Area, Is Associated With an Increase in Future Insulin Resistance in Japanese Americans. Diabetes, 2008, 57, 1269-1275.	0.3	177

#	Article	IF	Citations
199	Prevention of Diabetes in Women with a History of Gestational Diabetes: Effects of Metformin and Lifestyle Interventions. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 4774-4779.	1.8	696
200	Elevated Depression Symptoms, Antidepressant Medicine Use, and Risk of Developing Diabetes During the Diabetes Prevention Program. Diabetes Care, 2008, 31, 420-426.	4.3	193
201	The Dipeptidyl Peptidase-4 Inhibitor Vildagliptin Improves β-Cell Function and Insulin Sensitivity in Subjects With Impaired Fasting Glucose. Diabetes Care, 2008, 31, 108-113.	4.3	126
202	Glucose Control, Macro- and Microvascular Disease, and the Food and Drug Administration: Let's Keep Our Eye on the Ball. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 3727-3729.	1.8	2
203	Minimum Waist and Visceral Fat Values for Identifying Japanese Americans at Risk for the Metabolic Syndrome. Diabetes Care, 2007, 30, 120-127.	4.3	178
204	Point: Recent Long-Term Clinical Studies Support an Enhanced Role for Thiazolidinediones in the Management of Type 2 Diabetes. Diabetes Care, 2007, 30, 1672-1676.	4.3	5
205	Reduction in Weight and Cardiovascular Disease Risk Factors in Individuals With Type 2 Diabetes: One-year results of the Look AHEAD trial. Diabetes Care, 2007, 30, 1374-1383.	4.3	1,369
206	Differences in A1C by Race and Ethnicity Among Patients With Impaired Glucose Tolerance in the Diabetes Prevention Program. Diabetes Care, 2007, 30, 2453-2457.	4.3	479
207	Inhibition of glycosaminoglycan synthesis and protein glycosylation with WAS-406 and azaserine result in reduced islet amyloid formation in vitro. American Journal of Physiology - Cell Physiology, 2007, 293, C1586-C1593.	2.1	49
208	Effects of the Type 2 Diabetes-AssociatedPPARGP12A Polymorphism on Progression to Diabetes and Response to Troglitazone. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 1502-1509.	1.8	122
209	Factors Associated With Diabetes Onset During Metformin Versus Placebo Therapy in the Diabetes Prevention Program. Diabetes, 2007, 56, 1153-1159.	0.3	84
210	Progressive Loss of Â-Cell Function Leads to Worsening Glucose Tolerance in First-Degree Relatives of Subjects With Type 2 Diabetes. Diabetes Care, 2007, 30, 677-682.	4.3	152
211	Relationship of Liver Enzymes to Insulin Sensitivity and Intra-Abdominal Fat. Diabetes Care, 2007, 30, 2673-2678.	4.3	47
212	Identification of the Amyloid-Degrading Enzyme Neprilysin in Mouse Islets and Potential Role in Islet Amyloidogenesis. Diabetes, 2007, 56, 304-310.	0.3	33
213	Glucose- and time-dependence of islet amyloid formation in vitro. Biochemical and Biophysical Research Communications, 2007, 354, 234-239.	1.0	35
214	Superiority of the Modification of Diet in Renal Disease equation over the Cockcroft–Gault equation in screening for impaired kidney function in Japanese Americans. Diabetes Research and Clinical Practice, 2007, 77, 320-326.	1.1	11
215	Type 2 Diabetes–Associated Missense Polymorphisms KCNJ11 E23K and ABCC8 A1369S Influence Progression to Diabetes and Response to Interventions in the Diabetes Prevention Program. Diabetes, 2007, 56, 531-536.	0.3	115
216	Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy. New England Journal of Medicine, 2006, 355, 2427-2443.	13.9	2,714

#	Article	IF	Citations
217	Obesity Is a Major Determinant of the Association of C-Reactive Protein Levels and the Metabolic Syndrome in Type 2 Diabetes. Diabetes, 2006, 55, 2357-2364.	0.3	169
218	Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature, 2006, 444, 840-846.	13.7	4,032
219	Effects of Sex and Hormone Replacement Therapy Use on the Prevalence of Isolated Impaired Fasting Clucose and Isolated Impaired Glucose Tolerance in Subjects With a Family History of Type 2 Diabetes. Diabetes, 2006, 55, 3529-3535.	0.3	65
220	Of Hopes and DREAMS: The Quest to Prevent Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 4762-4763.	1.8	1
221	Population approaches to estimate minimal model indexes of insulin sensitivity and glucose effectiveness using full and reduced sampling schedules. American Journal of Physiology - Endocrinology and Metabolism, 2006, 291, E716-E723.	1.8	17
222	Adherence to Preventive Medications: Predictors and outcomes in the Diabetes Prevention Program. Diabetes Care, 2006, 29, 1997-2002.	4.3	136
223	Impact of Differences in Fasting Glucose and Glucose Tolerance on the Hyperbolic Relationship Between Insulin Sensitivity and Insulin Responses. Diabetes Care, 2006, 29, 356-362.	4.3	7 3
224	Gestational Diabetes Mellitus Increases the Risk of Cardiovascular Disease in Women With a Family History of Type 2 Diabetes. Diabetes Care, 2006, 29, 2078-2083.	4.3	284
225	The Role of Insulin Resistance in Nonalcoholic Fatty Liver Disease. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 4753-4761.	1.8	712
226	Genetic background determines the extent of islet amyloid formation in human islet amyloid polypeptide transgenic mice. American Journal of Physiology - Endocrinology and Metabolism, 2005, 289, E703-E709.	1.8	10
227	Insulin, C-Peptide, and Leptin Concentrations Predict Increased Visceral Adiposity at 5- and 10-Year Follow-Ups in Nondiabetic Japanese Americans. Diabetes, 2005, 54, 985-990.	0.3	43
228	Prevention of Type 2 Diabetes With Troglitazone in the Diabetes Prevention Program. Diabetes, 2005, 54, 1150-1156.	0.3	442
229	Effects of Short-Term Experimental Insulin Resistance and Family History of Diabetes on Pancreatic Î ² -Cell Function in Nondiabetic Individuals. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 5825-5833.	1.8	25
230	Role of Insulin Secretion and Sensitivity in the Evolution of Type 2 Diabetes in the Diabetes Prevention Program: Effects of Lifestyle Intervention and Metformin. Diabetes, 2005, 54, 2404-2414.	0.3	405
231	Long-Term Treatment With Rosiglitazone and Metformin Reduces the Extent of, but Does Not Prevent, Islet Amyloid Deposition in Mice Expressing the Gene for Human Islet Amyloid Polypeptide. Diabetes, 2005, 54, 2235-2244.	0.3	86
232	A Reduced-Fat Diet and Aerobic Exercise in Japanese Americans With Impaired Glucose Tolerance Decreases Intra-Abdominal Fat and Improves Insulin Sensitivity but not A-Cell Function. Diabetes, 2005, 54, 340-347.	0.3	61
233	Differential effect of inbred mouse strain (C57BL/6, DBA/2, 129T2) on insulin secretory function in response to a high fat diet. Journal of Endocrinology, 2005, 187, 45-53.	1.2	119
234	Cholesterol Feeding Increases C-Reactive Protein and Serum Amyloid A Levels in Lean Insulin-Sensitive Subjects. Circulation, 2005, 111, 3058-3062.	1.6	96

#	Article	IF	Citations
235	Is central obesity associated with cirrhosis-related death or hospitalization? A population-based, cohort study. Clinical Gastroenterology and Hepatology, 2005, 3, 67-74.	2.4	283
236	Contribution of metabolic factors to alanine aminotransferase activity in persons with other causes of liver disease. Gastroenterology, 2005, 128, 627-635.	0.6	68
237	Preserved Cognition in Patients With Early Alzheimer Disease and Amnestic Mild Cognitive Impairment During Treatment With Rosiglitazone. American Journal of Geriatric Psychiatry, 2005, 13, 950-958.	0.6	62
238	Diet-Induced Weight Loss Is Associated with an Improvement in \hat{l}^2 -Cell Function in Older Men. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 2704-2710.	1.8	70
239	Impact of Intra-Abdominal Fat and Age on Insulin Sensitivity and Â-Cell Function. Diabetes, 2004, 53, 2867-2872.	0.3	98
240	Intra-Abdominal Fat Is a Major Determinant of the National Cholesterol Education Program Adult Treatment Panel III Criteria for the Metabolic Syndrome. Diabetes, 2004, 53, 2087-2094.	0.3	813
241	Suppression of Beta-Cell Secretion by Somatostatin Does Not Fully Reverse the Disproportionate Proinsulinemia of Type 2 Diabetes. Diabetes, 2004, 53, S22-S25.	0.3	7
242	Islet Amyloid: A Critical Entity in the Pathogenesis of Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 3629-3643.	1.8	495
243	Phenotypic Characteristics of GAD Antibody-Positive Recently Diagnosed Patients With Type 2 Diabetes in North America and Europe. Diabetes, 2004, 53, 3193-3200.	0.3	154
244	Complex Distribution, Not Absolute Amount of Adiponectin, Correlates with Thiazolidinedione-mediated Improvement in Insulin Sensitivity. Journal of Biological Chemistry, 2004, 279, 12152-12162.	1.6	1,018
245	Engineering a new \hat{l}^2 -cell: a critical venture requiring special attention to constantly changing physiological needs. Seminars in Cell and Developmental Biology, 2004, 15, 359-370.	2.3	9
246	Visceral Adiposity Is an Independent Predictor of Incident Hypertension in Japanese Americans. Annals of Internal Medicine, 2004, 140, 992.	2.0	234
247	Management of patients with diabetic hyperlipidemia. American Journal of Cardiology, 2003, 91, 24-28.	0.7	10
248	Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes. Contemporary Clinical Trials, 2003, 24, 610-628.	2.0	698
249	The Atherogenic Lipoprotein Profile Associated With Obesity and Insulin Resistance Is Largely Attributable to Intra-Abdominal Fat. Diabetes, 2003, 52, 172-179.	0.3	243
250	Proteoglycans synthesized and secreted by pancreatic islet \hat{l}^2 -cells bind amylin. Archives of Biochemistry and Biophysics, 2003, 413, 182-190.	1.4	38
251	Comparison of a Clinical Model, the Oral Glucose Tolerance Test, and Fasting Glucose for Prediction of Type 2 Diabetes Risk in Japanese Americans. Diabetes Care, 2003, 26, 758-763.	4.3	95
252	Effects of Insulin Resistance and Obesity on Lipoproteins and Sensitivity to Egg Feeding. Arteriosclerosis, Thrombosis, and Vascular Biology, 2003, 23, 1437-1443.	1.1	92

#	Article	IF	Citations
253	Increased Dietary Fat Promotes Islet Amyloid Formation and Â-Cell Secretory Dysfunction in a Transgenic Mouse Model of Islet Amyloid. Diabetes, 2003, 52, 372-379.	0.3	105
254	Visceral Adiposity and the Risk of Impaired Glucose Tolerance: A prospective study among Japanese Americans. Diabetes Care, 2003, 26, 650-655.	4.3	191
255	Visceral Adiposity and the Prevalence of Hypertension in Japanese Americans. Circulation, 2003, 108, 1718-1723.	1.6	121
256	PLTP activity decreases with weight loss. Journal of Lipid Research, 2003, 44, 1705-1712.	2.0	34
257	Continuous Measurement of Oxygen Consumption by Pancreatic Islets. Diabetes Technology and Therapeutics, 2002, 4, 661-672.	2.4	92
258	A Diabetes Outcome Progression Trial (ADOPT): An international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care, 2002, 25, 1737-1743.	4.3	215
259	Â-Cell Function Is a Major Contributor to Oral Glucose Tolerance in High-Risk Relatives of Four Ethnic Groups in the U.S Diabetes, 2002, 51, 2170-2178.	0.3	286
260	Insulin and Amylin Release Are Both Diminished in First-Degree Relatives of Subjects With Type 2 Diabetes. Diabetes Care, 2002, 25, 292-297.	4.3	37
261	Improvement of BMI, Body Composition, and Body Fat Distribution With Lifestyle Modification in Japanese Americans With Impaired Glucose Tolerance. Diabetes Care, 2002, 25, 1504-1510.	4.3	69
262	The Concurrent Accumulation of Intra-Abdominal and Subcutaneous Fat Explains the Association Between Insulin Resistance and Plasma Leptin Concentrations: Distinct Metabolic Effects of Two Fat Compartments. Diabetes, 2002, 51, 1005-1015.	0.3	362
263	The Importance of \hat{i}^2 -Cell Failure in the Development and Progression of Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 4047-4058.	1.8	536
264	Obesity, Body Fat Distribution, Insulin Sensitivity and Islet \hat{l}^2 -Cell Function as Explanations for Metabolic Diversity. Journal of Nutrition, 2001, 131, 354S-36OS.	1.3	181
265	Relationship of Insulin Sensitivity and ApoB Levels to Intra-abdominal Fat in Subjects With Familial Combined Hyperlipidemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 2001, 21, 567-572.	1.1	60
266	Importance of Early Phase Insulin Secretion to Intravenous Glucose Tolerance in Subjects with Type 2 Diabetes Mellitus. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 5824-5829.	1.8	87
267	Regulation of Insulin Secretion in Vivo. Growth Hormone, 2001, , 109-131.	0.2	5
268	Importance of Early Phase Insulin Secretion to Intravenous Glucose Tolerance in Subjects with Type 2 Diabetes Mellitus. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 5824-5829.	1.8	38
269	Reduced Pancreatic B Cell Compensation to the Insulin Resistance of Aging: Impact on Proinsulin and Insulin Levels ¹ . Journal of Clinical Endocrinology and Metabolism, 2000, 85, 2275-2280.	1.8	44
270	Effect of Weight Loss with Reduction of Intra-Abdominal Fat on Lipid Metabolism in Older Men*. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 977-982.	1.8	125

#	Article	IF	Citations
271	The importance of the \hat{l}^2 -cell in the pathogenesis of type 2 diabetes mellitus 11 Supported in part by National Institutes of Health grants DK-02654, DK-17047, DK-50703, and the Medical Research Service of the Department of Veterans Affairs American Journal of Medicine, 2000, 108, 2-8.	0.6	175
272	Type 2 diabetes and the metabolic syndrome in Japanese Americans. Diabetes Research and Clinical Practice, 2000, 50, S73-S76.	1.1	66
273	Reduced \hat{I}^2 -cell function contributes to impaired glucose tolerance in dogs made obese by high-fat feeding. American Journal of Physiology - Endocrinology and Metabolism, 1999, 277, E659-E667.	1.8	34
274	Heritability of Pancreatic \hat{l}^2 -Cell Function among Nondiabetic Members of Caucasian Familial Type 2 Diabetic Kindreds1. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 1398-1403.	1.8	125
275	Insulin resistance and obesity. Nature, 1999, 402, 860-861.	13.7	38
276	Disproportionately Elevated Proinsulin Levels Reflect the Degree of Impaired B Cell Secretory Capacity in Patients with Noninsulin-Dependent Diabetes Mellitus ¹ . Journal of Clinical Endocrinology and Metabolism, 1998, 83, 604-608.	1.8	175
277	Effect of Troglitazone on B Cell Function, Insulin Sensitivity, and Glycemic Control in Subjects with Type 2 Diabetes Mellitus ¹ . Journal of Clinical Endocrinology and Metabolism, 1998, 83, 819-823.	1.8	62
278	Human aging is associated with parallel reductions in insulin and amylin release. American Journal of Physiology - Endocrinology and Metabolism, 1998, 275, E785-E791.	1.8	30
279	Des-(27-31)C-Peptide. Journal of Biological Chemistry, 1996, 271, 27475-27481.	1.6	25
280	Proinsulin as a Marker for the Development of NIDDM in Japanese-American Men. Diabetes, 1995, 44, 173-179.	0.3	125
281	Changes in insulin sensitivity, glucose effectiveness, and B-cell function in regularly exercising subjects. Metabolism: Clinical and Experimental, 1995, 44, 1259-1263.	1.5	30
282	The Contribution of Insulin-Dependent and Insulin-Independent Glucose Uptake to Intravenous Glucose Tolerance in Healthy Human Subjects. Diabetes, 1994, 43, 587-592.	0.3	112
283	The Visceral Adiposity Syndrome in Japaneseâ€American Men. Obesity, 1994, 2, 364-371.	4.0	89
284	Effect of heparin on insulin-glucose interactions measured by the minimal model technique: Implications for reproducibility using this method. Metabolism: Clinical and Experimental, 1993, 42, 353-357.	1.5	39
285	Prospective evaluation of \hat{l}^2 -cell function in insulin antoantibody-positive relatives of insulin-dependent diabetic patients. Metabolism: Clinical and Experimental, 1993, 42, 482-486.	1.5	11
286	Effect of Human Growth Hormone and Insulin-Like Growth Factor I on Whole-Body Leucine and Estimates of Protein Metabolism. Hormone Research, 1993, 40, 92-94.	1.8	11
287	Fibrinolytic response during exercise and epinephrine infusion in the same subjects. Journal of the American College of Cardiology, 1992, 19, 1412-1420.	1.2	66
288	Effect of intensive endurance training on lipoprotein profiles in young and older men. Metabolism: Clinical and Experimental, 1992, 41, 649-654.	1.5	40

#	ARTICLE	IF	CITATIONS
289	Mechanisms for hyperglycemia in type II diabetes mellitus: Therapeutic implications for sulfonylurea treatmentâ€"an update. American Journal of Medicine, 1991, 90, S8-S14.	0.6	25
290	The effect of intensive endurance exercise training on body fat distribution in young and older men. Metabolism: Clinical and Experimental, 1991, 40, 545-551.	1.5	252
291	CENTRAL INSULIN ADMINISTRATION REDUCES NEUROPEPTIDE Y mRNA EXPRESSION IN THE ARCUATE NUCLEUS OF FOOD-DEPRIVED LEAN (Fa/Fa) BUT NOT OBESE (fa/fa) ZUCKER RATS. Endocrinology, 1991, 128, 2645-2647.	1.4	248
292	Disproportionately Elevated Proinsulin in Pima Indians with Noninsulin-Dependent Diabetes Mellitus*. Journal of Clinical Endocrinology and Metabolism, 1990, 70, 1247-1253.	1.8	198
293	Treatment with a Somatostatin Analog Decreases Pancreatic B-Cell and Whole Body Sensitivity to Glucose*. Journal of Clinical Endocrinology and Metabolism, 1990, 71, 994-1002.	1.8	99
294	Insulin binding to brain capillaries is reduced in genetically obese, hyperinsulinemic Zucker rats. Peptides, 1990, 11, 467-472.	1.2	111
295	Islet dysfunction in non-insulin-dependent diabetes mellitus. American Journal of Medicine, 1988, 85, 4-8.	0.6	27
296	Transfemoral embolectomy for massive pulmonary embolus and associated myocardial infarction. American Heart Journal, 1987, 113, 819-822.	1.2	5
297	Superior vena caval obstruction secondary to acute dissecting aneurysm of the aorta. American Heart Journal, 1986, 111, 606-608.	1.2	19
298	Low-dose streptokinase therapy for Swan-Ganz catheter-induced thrombosis. American Heart Journal, 1985, 110, 891-893.	1.2	8